Indolent Lymphoma - Pipeline Review, H1 2016

Indolent Lymphoma - Pipeline Review, H1 2016

Feb 2016 Global Markets Direct Lymphoma218 Pages Price :
$ 2000
Indolent Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Directs, Indolent Lymphoma - Pipeline Review, H1 2016, provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Indolent Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Indolent Lymphoma - Overview 11
Indolent Lymphoma - Therapeutics under Development by Companies 12
Indolent Lymphoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Indolent Lymphoma - Products under Development by Companies 16
Indolent Lymphoma - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Affimed Therapeutics AG 19
Altor BioScience Corporation 20
Astellas Pharma Inc. 21
AstraZeneca Plc 22
Bayer AG 23
Biothera, Inc. 24
Boehringer Ingelheim GmbH 25
Bristol-Myers Squibb Company 26
Celgene Corporation 27
F. Hoffmann-La Roche Ltd. 28
Gilead Sciences, Inc. 29
Incyte Corporation 30
Infinity Pharmaceuticals, Inc. 31
Juno Therapeutics Inc. 32
Kite Pharma, Inc. 33
MedImmune, LLC 34
Merck & Co., Inc. 35
Merck KGaA 36
Millennium Pharmaceuticals, Inc. 37
MorphoSys AG 38
Trillium Therapeutics Inc. 39
Indolent Lymphoma - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
acalisib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AFM-11 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ALT-803 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AZD-6738 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
bendamustine hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BI-836826 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BMS-986016 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BTH-1677 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CC-122 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
copanlisib hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DI-B4 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
duvelisib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
entospletinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ibrutinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
idelalisib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
INCB-40093 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
INCB-50465 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
inebilizumab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
inebilizumab + MEDI-0680 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
inebilizumab + rituximab - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
itacitinib adipate - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
JCAR-014 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
JCAR-015 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
KTEC-19 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
lenalidomide - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
MOR-208 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
obinutuzumab - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
TAK-659 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
TTI-621 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
venetoclax - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
vorinostat - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Indolent Lymphoma - Recent Pipeline Updates 126
Indolent Lymphoma - Dormant Projects 204
Indolent Lymphoma - Discontinued Products 205
Indolent Lymphoma - Product Development Milestones 206
Featured News & Press Releases 206
Nov 30, 2015: New Data from Bayers Portfolio in Oncology to be Presented at ASH 2015 206
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 206
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 206
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 207
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 208
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkins Lymphoma 210
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 211
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 212
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 213
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkins Lymphomas At ASH 215
Appendix 217
Methodology 217
Coverage 217
Secondary Research 217
Primary Research 217
Expert Panel Validation 217
Contact Us 217
Disclaimer 218

List of Tables
Number of Products under Development for Indolent Lymphoma, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Indolent Lymphoma - Pipeline by AbbVie Inc., H1 2016 18
Indolent Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 19
Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016 20
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 21
Indolent Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 22
Indolent Lymphoma - Pipeline by Bayer AG, H1 2016 23
Indolent Lymphoma - Pipeline by Biothera, Inc., H1 2016 24
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 25
Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 26
Indolent Lymphoma - Pipeline by Celgene Corporation, H1 2016 27
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 28
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 29
Indolent Lymphoma - Pipeline by Incyte Corporation, H1 2016 30
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 31
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 32
Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 33
Indolent Lymphoma - Pipeline by MedImmune, LLC, H1 2016 34
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 35
Indolent Lymphoma - Pipeline by Merck KGaA, H1 2016 36
Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 37
Indolent Lymphoma - Pipeline by MorphoSys AG, H1 2016 38
Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 39
Assessment by Monotherapy Products, H1 2016 40
Assessment by Combination Products, H1 2016 41
Number of Products by Stage and Target, H1 2016 43
Number of Products by Stage and Mechanism of Action, H1 2016 46
Number of Products by Stage and Route of Administration, H1 2016 48
Number of Products by Stage and Molecule Type, H1 2016 50
Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 126
Indolent Lymphoma - Dormant Projects, H1 2016 204
Indolent Lymphoma - Discontinued Products, H1 2016 205

List of Figures
Number of Products under Development for Indolent Lymphoma, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Assessment by Monotherapy Products, H1 2016 40
Number of Products by Top 10 Targets, H1 2016 42
Number of Products by Stage and Top 10 Targets, H1 2016 42
Number of Products by Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Routes of Administration, H1 2016 47
Number of Products by Stage and Routes of Administration, H1 2016 47
Number of Products by Molecule Types, H1 2016 49
Number of Products by Stage and Molecule Types, H1 2016 49

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top